WHO ICTRP trial
Safety study for the use of Rapamycin in children with familial adenomatous…
CTIS2024-512079-11-00 · EU Clinical Trials Information System · Not Recruiting
Key facts
| Trial ID | CTIS2024-512079-11-00 |
|---|---|
| Public title | Safety study for the use of Rapamycin in children with familial adenomatous polyposis - RAPA-4-FAP |
| Scientific title | Safety study for the use of Rapamycin in children with familial adenomatous polyposis - RAPA-4-FAP - RC31/23/0388 |
| Primary sponsor | Centre Hospitalier Universitaire De Toulouse |
| Registry | EU Clinical Trials Information System |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): No Therapeutic exploratory (Phase II): Yes Therapeutic confirmatory - (Phase III): No Therapeutic use - (Phase IV): No |
| Countries | France |
| Conditions | Familial adenomatous polyposis MedDRA version: 20.1Level: LLTClassification code: 10059327Term: Familial adenomatous polyposis Class: 10010331;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] |
| Interventions | Product Name: Rapamune 2 mg coated tablets, Product Code:PRD3342085, Pharmaceutical Form: COATED TABLET, Other descriptive name: , Strength: |
| Registration date | Jun 6, 2024 |
| Target size | 25 |
| Secondary IDs | NCT06308445 |
| Registry page | euclinicaltrials.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: